Production (Stage)
NurExone Biologic Inc.
NRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.39% | -38.58% | -8.12% | -8.97% | 41.21% |
| Total Depreciation and Amortization | 169.05% | 157.58% | 58.06% | 226.67% | 250.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.31% | 50.23% | 102.35% | 143.84% | -31.77% |
| Change in Net Operating Assets | 98.96% | -23,175.00% | -227.00% | -209.22% | -409.68% |
| Cash from Operations | -23.05% | -66.20% | -22.25% | -19.69% | -2.28% |
| Capital Expenditure | -42.39% | -440.83% | -1,325.53% | -545.61% | -197.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -139.13% | -139.13% | -- | 135.14% | 162.16% |
| Cash from Investing | -56.99% | -578.35% | -1,297.87% | -277.66% | -102.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 10.71% | -7.14% | -55.00% | -183.33% | -21.74% |
| Issuance of Common Stock | -40.32% | 534.55% | 610.35% | 9,874.55% | 180.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -994.74% | -994.74% | -46.74% | -92.38% | -94.46% |
| Cash from Financing | -56.84% | 419.26% | 407.98% | 219.76% | 48.23% |
| Foreign Exchange rate Adjustments | -9,850.00% | -981.25% | 900.00% | 166.67% | 96.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -259.99% | 108.27% | 168.73% | 197.85% | 6,311.54% |